No Data
No Data
Vanda Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
Vanda Pharmaceuticals Initiated at Overweight by Cantor
Vanda Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 105.61% Cantor Fitzgerald → $11 Initiates Coverage On → Overweight 02/25/2022 124.3%
Cantor Fitzgerald Initiates Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Announces Target Price $11
Cantor Fitzgerald analyst Charles Duncan initiates coverage on $Vanda Pharmaceuticals(VNDA.US)$ with a buy rating, and sets the target price at $11.According to TipRanks data, the analyst has a
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda Intends to Proceed With Discovery in the Case to Continue Pursuing Its Claims >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
Vanda: Court Concluded Issues of Patentability Weren't Same as Those Resolved in Prior Patent-Infringement Litigation Between Parties >VNDA
No Data
Zamm : Add to my WL . Thanks